Reports emerge that Isomorphic Labs, the drug-discovery company spun out of Google DeepMind, is in talks to raise roughly $5 billion in new funding at a valuation of about $50 billion. The round has not closed, the investors have not been named, and the terms could still change. If it lands on the reported terms, it would be one of the largest private financings ever for a European company — and a striking price for a business that has yet to test one of its own drug candidates in a human being.
What the reported round looks like
Bloomberg reported on 4 November, citing people familiar with the matter, that Isomorphic is in talks to raise roughly $5 billion at about $50 billion. Neither Isomorphic nor Alphabet has confirmed the talks, and the financing has not closed. The report firms up an October report of early talks at $40 billion or more.
A $5 billion raise would be about 2.4 times the $2.1 billion Series B Isomorphic closed in May, and would lift total external funding since March 2025 to about $7.7 billion. The $50 billion figure sits at the top of the valuation range reported in October.
A $2.7 billion ladder in under two years
Isomorphic’s first external round was $600 million in March 2025, led by Thrive Capital with GV and Alphabet. Its $2.1 billion Series B closed on 12 May 2026, again led by Thrive, with Alphabet, GV, MGX, Temasek, CapitalG and the UK Sovereign AI Fund joining. Neither round disclosed a valuation.
The company, founded in London in 2021, employs more than 350 people across London, Cambridge in Massachusetts, and Lausanne. It is led by Demis Hassabis, who runs Google DeepMind as well and shared the 2024 Nobel Prize in Chemistry for AlphaFold, the protein-structure AI the company is built on.
What the money would buy
Isomorphic designs drugs through IsoDDE, the Isomorphic Drug Design Engine, a suite of AI models that predict molecular structures and interactions to design and refine candidates before any laboratory work. Its in-house programmes focus on cancer and immune disorders, and it works with Eli Lilly, Novartis and Johnson & Johnson. Other drug-discovery platforms are consolidating around the same idea.
The partnerships carry large milestone payments — up to $1.7 billion from Eli Lilly and up to $1.2 billion from Novartis, both signed in January 2024, with Johnson & Johnson joining in January 2026 on undisclosed terms. Those payments depend on hitting development milestones.
Hassabis expects the company’s first clinical trials to start by the end of December. A trial would only show that Isomorphic can get a candidate into human testing — it would not prove that an AI-designed drug works in people.
Our Read
The valuation is the story. At $50 billion, Isomorphic would be worth over three times the AI drug-discovery market’s forecast sales for 2033 — $2.3 billion in 2025, growing to $13.8 billion, according to Grand View Research. Investors are paying frontier-AI prices for biotech timelines, betting AI can compress drug development from years to months.
Chai Discovery raised $400 million in July at a $3.8 billion valuation; London’s Basecamp Research raised $140 million in September at $800 million. Isomorphic’s reported tag is roughly 13 times Chai’s and more than 60 times Basecamp’s. Thinking Machines Lab is advancing a $5 billion round of its own at a $40 billion valuation.
The risk is plain. No AI drug developer has brought a medicine to market, and few have reached the clinic. Isomorphic has already slipped once on its trial timetable, and a further delay would leave the valuation resting on partnerships and claims not yet validated in people.
Rivals are moving too. Anthropic’s Claude has taken on drug-discovery work, and OpenAI launched a life-sciences research model this year — so Isomorphic’s head start is a lead in a crowded race, not a moat, and the first trial will be watched closely.
Why It Matters
A $5 billion close would be one of the largest private financings ever for a European company and one of biotech’s richest private valuations. It would also reprice the whole AI drug-discovery field five months after Isomorphic’s own $2.1 billion round, signalling that investors now treat drug design as a frontier-AI market rather than a biotech niche.
The funding climate supports that reading. OpenAI has just closed an initial $11 billion of a round valuing it at $1.25 trillion. For patients, the stakes are longer term: if Isomorphic’s engine works, the payoff is faster, cheaper medicines for more people.
Background
Isomorphic Labs spun out of Google DeepMind in 2021 to build on AlphaFold, the AI that predicts protein structures. Hassabis shared the 2024 Nobel Prize in Chemistry for that work, and has said his goal is to cut drug development from years to months. AI-designed proteins are already showing lab results elsewhere.
Source: Dealroom’s account and Tech Funding News
0 Comments